Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
BioMarin Pharmaceutical ( (BMRN) ) just unveiled an update.
On December 19, 2025, BioMarin Pharmaceutical Inc., a biopharmaceutical company focused on therapies for rare genetic and metabolic diseases, announced it would discontinue development of BMN 349, an oral therapeutic candidate for Alpha-1 antitrypsin deficiency-associated liver disease. The decision to halt this program removes a potential future product from BioMarin’s pipeline in the AATD liver disease space, signaling a strategic shift in its research and development focus that may prompt investors and stakeholders to reassess expectations for the company’s near- to mid-term portfolio mix and growth drivers.
The most recent analyst rating on (BMRN) stock is a Hold with a $60.00 price target. To see the full list of analyst forecasts on BioMarin Pharmaceutical stock, see the BMRN Stock Forecast page.
Spark’s Take on BMRN Stock
According to Spark, TipRanks’ AI Analyst, BMRN is a Outperform.
BioMarin Pharmaceutical’s strong financial performance and strategic acquisition of Amicus Therapeutics are significant positives, supporting its growth trajectory. However, technical indicators suggest the stock may be overbought, and valuation metrics indicate moderate attractiveness. Earnings call insights reveal both strengths and challenges, balancing the overall sentiment.
To see Spark’s full report on BMRN stock, click here.
More about BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc. is a biopharmaceutical company that develops and commercializes innovative therapies, primarily targeting rare genetic and metabolic diseases with high unmet medical need.
Average Trading Volume: 2,880,917
Technical Sentiment Signal: Sell
Current Market Cap: $11.75B
See more data about BMRN stock on TipRanks’ Stock Analysis page.